Bolt Biotherapeutics, Inc. (BOLT)
NASDAQ: BOLT · Real-Time Price · USD
3.990
+0.100 (2.57%)
At close: Jul 31, 2026, 4:00 PM EDT
3.900
-0.090 (-2.26%)
After-hours: Jul 31, 2026, 6:26 PM EDT

Bolt Biotherapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
6.57.77.697.885.731.26
Revenue Growth
78.64%0.07%-2.36%37.48%354.68%445.46%
Gross Profit
6.57.77.697.885.731.26
Operating Income
-31.6-36.11-73.05-76.2-90.32-92.79
Net Income
-29.58-33.38-63.12-69.2-88.1-98.59
Earnings Per Share
-16.33-17.85-33.06-36.60-47.20-59.40
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
22.8927.5147.32102.19168.89186.22
Total Debt
22.3122.9625.2120.2222.6124.36
Net Cash (Debt)
0.584.5522.1181.97146.28161.86
Net Cash Growth
-95.87%-79.44%-73.02%-43.96%-9.63%1253.27%
Net Cash Per Share
0.322.4311.5843.3678.3197.52

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-34.51-39.85-61.29-69.53-76.5-57.07
Capital Expenditures
--0.07-0.04-0.21-1.95-2.34
Free Cash Flow
-34.51-39.92-61.33-69.73-78.46-59.4
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-486.21%-469.31%-949.91%-967.45%-1576.56%-7364.13%
Pretax Margin
-457.73%-433.74%-820.78%-878.58%-1537.76%-7824.68%
Profit Margin
-457.73%-433.74%-820.78%-878.58%-1537.76%-7824.68%
FCF Margin
-530.97%-518.80%-797.53%-885.36%-1369.47%-4714.60%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
1.181.362.675.428.58145.44